Medically reviewed by Aloysius Fobi, MD, Medical Director and Prescribing Physician | Reviewed by Lily Gazaryan, Founder and Aesthetics Specialist | 15+ Years Medical Industry | Last Updated: May 2026
Quick Answer
In head-to-head clinical trials, tirzepatide produces greater weight loss than semaglutide: roughly 20% body weight loss at 72 weeks vs. roughly 14% for semaglutide. Semaglutide acts on one receptor (GLP-1). Tirzepatide acts on two (GLP-1 and GIP), which is why it tends to be more effective for weight loss. Both medications carry similar gastrointestinal side effects (nausea, constipation, occasional vomiting), with tirzepatide having slightly higher rates at the highest doses. Cost in Los Angeles is comparable. The right medication depends on your weight loss goal, medical history, and how your body responds during the first 12 weeks.
Patients in Los Angeles considering medical weight loss face a real decision: semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound)? The two medications are often discussed together but they are not interchangeable. This guide walks through what each is, how the two compare in published clinical data, side effect profiles, and how Dr. Aloysius Fobi structures medical weight loss programs at ALGM Beauty Bar in Van Nuys.
What Each Medication Is
Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone your gut releases after meals. It signals fullness to the brain, slows stomach emptying, and helps the pancreas regulate blood sugar. Semaglutide mimics this hormone and extends its effect. Brand names: Ozempic (FDA-approved for type 2 diabetes) and Wegovy (FDA-approved for chronic weight management).
Tirzepatide is a dual GLP-1 and GIP receptor agonist. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that works alongside GLP-1 to regulate appetite, insulin response, and energy use. Tirzepatide is the first FDA-approved medication that activates both receptors at once. Brand names: Mounjaro (FDA-approved for type 2 diabetes) and Zepbound (FDA-approved for chronic weight management).
Head-to-Head Weight Loss: What the Data Shows
The most-cited comparison comes from the SURMOUNT-5 trial published in the New England Journal of Medicine in 2025, the first direct head-to-head comparison between tirzepatide and semaglutide for weight loss in adults with obesity but not type 2 diabetes.
Findings at 72 weeks:
| Outcome | Tirzepatide | Semaglutide |
|---|---|---|
| Average body weight loss at 72 weeks | 20.2% | 13.7% |
| Patients losing 15% or more of body weight | ~65% | ~40% |
| Patients losing 25% or more of body weight | ~32% | ~16% |
Real-world meta-analyses combining multiple studies show similar results. Tirzepatide produces roughly 4 to 6 percentage points greater body weight loss than semaglutide on average, with a higher percentage of patients reaching the 15% and 20% weight loss thresholds.
This does not mean tirzepatide is the right choice for every patient. The right answer depends on your baseline weight, weight loss goal, and how your body tolerates the medication.
Side Effect Profiles Compared
Both medications produce gastrointestinal side effects, especially during the first 4 to 8 weeks of treatment and during dose escalations. The most common are:
- Nausea (most common, especially weeks 1 to 4 and after dose increases)
- Constipation
- Diarrhea
- Vomiting (less common, usually only during the first weeks or after dose escalation)
- Reflux or “GLP-1 burp”
- Decreased appetite (this is part of the mechanism, not technically a side effect)
- Fatigue during the first 1 to 2 weeks
In trials, tirzepatide had slightly higher rates of nausea and vomiting at the highest doses (15 mg and above) but the difference was modest. Most patients tolerate dose escalations well when they are done gradually with a 4-week step-up schedule.
Less common but serious side effects for both medications include pancreatitis, gallbladder issues, and (in rare cases) thyroid C-cell tumors in patients with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome. These conditions are screening exclusions during your initial consultation.
Cost in the Los Angeles Market
Pricing for medical weight loss medications has shifted significantly with the introduction of compounded versions and the manufacturer programs. Currently in the LA market:
- Brand-name Wegovy or Zepbound: $1,000 to $1,500 per month without insurance (manufacturer programs available)
- Compounded semaglutide: typically $300 to $500 per month at most LA medical weight loss clinics
- Compounded tirzepatide: typically $500 to $800 per month at most LA medical weight loss clinics
Insurance coverage for weight loss versions (Wegovy, Zepbound) is improving but remains inconsistent. Coverage for diabetes-indicated versions (Ozempic, Mounjaro) requires a type 2 diabetes diagnosis. Pricing depends on the medication source, the dose you are on, and any clinic-specific programs. Always confirm exact pricing during your consultation.
Who Each Is Best For
Semaglutide may be the better starting point for:
- Patients with established cardiovascular disease (semaglutide has documented cardiovascular benefit)
- Patients with sensitive GI systems who want the milder of the two options
- Patients with smaller weight loss goals (10 to 15% body weight)
- Patients with type 2 diabetes (Ozempic is a first-line option)
Tirzepatide may be the better starting point for:
- Patients with larger weight loss goals (more than 15% body weight)
- Patients who have plateaued on semaglutide and need additional efficacy
- Patients with metabolic syndrome (tirzepatide has stronger effect on insulin sensitivity)
- Patients without a personal cardiovascular history requiring the documented semaglutide benefit
Many ALGM patients start with whichever medication is most accessible to them and then reassess at the 12-week mark. If weight loss is on track and side effects are manageable, you stay on the same medication. If you have plateaued or are not tolerating well, your provider may recommend switching.
Why “Just the Shot” Is Not Enough
Both medications work best as part of a structured medical weight loss program, not as a standalone shot. The structure typically includes:
- Initial medical workup: labs (A1C, lipid panel, kidney function, thyroid), medical history, medication review
- Dose escalation schedule: standard step-ups every 4 weeks to reach therapeutic dose with minimal side effects
- Monthly check-ins: weight tracking, side effect review, dose adjustment if needed
- Nutrition guidance: protein priorities (key for preserving lean mass), hydration, sodium
- Activity recommendations: resistance training is essential to preserve lean mass during rapid weight loss
- Maintenance planning: what happens after you reach your goal weight
Patients who skip the structured component (lab monitoring, monthly check-ins, nutrition guidance) often regain weight when they discontinue the medication. The medication is the tool; the program is what makes the result stick.
Dr. Fobi’s perspective: “These medications are the most powerful weight loss tools we have ever had in medicine. They also work best when paired with the structure of a real medical weight loss program. The patients who get the best long-term results are the ones who treat the medication as a piece of a broader plan, not the entire plan.”
Frequently Asked Questions
Is tirzepatide better than semaglutide?
For pure weight loss outcomes in published trials, tirzepatide produces greater average weight loss (roughly 20% vs. 14% at 72 weeks). For other considerations like cardiovascular benefit (semaglutide), GI tolerance, and clinical history, the answer depends on the patient.
Can I switch from semaglutide to tirzepatide?
Yes. Many patients start on semaglutide and switch to tirzepatide if they plateau or want to reach a larger weight loss goal. The switch is typically managed with a brief washout and a fresh dose-escalation schedule.
How long do I have to stay on the medication?
For chronic weight management, the medications are intended for long-term use. Most patients see weight regain when discontinued, similar to how blood pressure rises when blood pressure medication is stopped. Maintenance dosing (lower than therapeutic) is an option for some patients.
What does the dose escalation schedule look like?
Both medications start at the lowest dose (semaglutide 0.25 mg weekly; tirzepatide 2.5 mg weekly) and step up every 4 weeks until reaching the therapeutic dose. Slower escalation helps minimize GI side effects.
Will I lose muscle along with fat?
Some lean mass loss is normal during any rapid weight loss. Protein intake (target 0.8 to 1.0 grams per pound of goal body weight) and resistance training are the two interventions that preserve lean mass. Both should be part of the program from week 1.
Is compounded semaglutide or tirzepatide as effective as the brand-name version?
Compounded versions use the same active pharmaceutical ingredient as the brand-name versions, sourced from FDA-registered facilities. Quality depends on the compounding pharmacy your clinic uses. Ask your provider where their compounded medication is sourced and request a copy of the certificate of analysis.
Visit ALGM Beauty Bar for Medical Weight Loss in Van Nuys
ALGM Beauty Bar offers medical weight loss programs at our Van Nuys location, serving clients across Los Angeles, Sherman Oaks, Studio City, North Hollywood, Burbank, and Encino. All weight loss programs are supervised by Dr. Aloysius Fobi, MD, including initial medical workup, dose escalation, monthly check-ins, and program maintenance.
For specific medications, see our Semaglutide (Ozempic) and Tirzepatide service pages, or our broader Hollywood Weight Loss Clinic overview.
Address: 7400 Van Nuys Blvd, Suite 112, Van Nuys, CA 91405
Phone: (747) 755-5333
Book medical weight loss consultation: Schedule your consultation.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical concerns. Individual results vary.
